The Effect of Efudex Treatment on Photoaged Skin

Status Completed

Clinical Trial Summary

The researchers propose that skin improvements may be seen following a course of Efudex, (5-fluorouracil), a FDA-approved topical therapy (applied directly to the skin). These improvements could be the result of both a reduction of actinic keratoses (small red horny growths or flesh-colored wartlike growths caused by overexposure to ultraviolet radiation or the sun) and improvement of sun-damaged skin.

In addition, this research study is being done to determine if the expression of p53, a tumor suppressor gene (its activity stops the formation of tumors), is decreased following Efudex treatment. Mutations (abnormal changes) in the gene, called p53, are associated with a certain type of skin cancer. In addition, p53-mutated genes are known to exist in non-cancerous sun-damaged skin. Thus, the presence of p53 mutations may serve as a marker for both sun damage and an elevated risk of developing skin cancer.

Clinical Trial Description

Efudex (5-fluorouracil) has been used as topical chemotherapy for the treatment of actinic keratoses (AKs) since the 1950's. Through many years of use, Efudex has been deemed to be a safe and effective therapy. It requires, however, a high level of patient compliance and is known to cause a vigorous inflammatory reaction when actinic keratoses are treated. It has the distinct advantage of identifying precancerous skin lesions not apparent on clinical inspection or palpation. Following a course of Efudex to the face, patients have been noted to have fewer signs of dermatoheliosis.

The investigators propose to determine if Efudex is associated with improvement of aging skin in the setting of treating actinic keratoses. The researchers hope to demonstrate less p53 staining following Efudex treatment. It is proposed that the skin improvements seen following a course of Efudex are due to both reduction of actinic keratoses and impact on photoaging. The researchers propose to quantify the effects of Efudex therapy on the immunohistochemical staining properties of facial skin with respect to p53 and procollagen. The hypothesis is that Efudex therapy will decrease p53 immunostaining thus providing biochemical evidence to support this treatment in the reduction of actinic keratoses with concomitant improvement of aging skin. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00121511
Study type	Interventional
Source	University of Michigan
Contact
Status	Completed
Phase	N/A
Start date	July 2005
Completion date	July 2007

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00239135` - Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel	Phase 2
Recruiting	`NCT06206681` - Efficacy and Safety of Ultrapulse Carbon Dioxide Laser Treatment in Eyelid Tumors
Completed	`NCT00115154` - Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Arms and Hands	Phase 4
Recruiting	`NCT04336514` - A Longitudinal Quantitative Assessment of the Effectiveness of Metatarsal Pads on Plantar Pressures	N/A
Completed	`NCT00116649` - Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis	Phase 4
Recruiting	`NCT05942794` - Identification of Oral Lesions Through an Autofluorescence System	N/A
Withdrawn	`NCT02851693` - Study of Imaging Characteristics OCT of Skin Lesions Requiring Biopsy / Resection	N/A
Withdrawn	`NCT02813902` - A Trial of Polypodium Leucotomos in Preventing Skin Cancer and Its Precursors	Phase 1
Completed	`NCT00114023` - 1-Year Follow up to the 1473-IMIQ Study	Phase 3
Completed	`NCT05060237` - Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp	Phase 1
Recruiting	`NCT02737176` - Tobacco Cessation Intervention Study for Oral Diseases	N/A
Completed	`NCT00110682` - Study of Imiquimod 5% Cream in Addition to Cryotherapy in the Management of Actinic Keratoses	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.